SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (567)4/7/1998 9:56:00 AM
From: Henry Niman  Respond to of 1491
 
Although not quite on the market yet, Targretin, in animal models of breast cancer, reverses the uterine stimulation of Tamoxifen. It also is as effective as Tamoxifen in preventing breast cancer, is more effective in treating breast, and synergizes with Tamoxifen for prevention. LLY has a program with LGND to look at combining a SERM like Evista and a rexinoid like Targretin.



To: yosi s who wrote (567)4/7/1998 6:03:00 PM
From: David Israel-Rosen  Read Replies (2) | Respond to of 1491
 
Dear Yosi and Arriela:

Last night Lemont issued a report on PARS with a $6 plus price target. Call Gary David @ 800-356-2092 to get your copy


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News